BRISTOL-MYERS Squibb has
announced that the Therapeutic
Goods Administration (TGA) has
approved Opdivo (nivolumab) for
management of difficult-to treat
malignancies: advanced lung cancer
and advanced melanoma under
specific circumstances.
MEANWHILE Novartis has
announced the PBS funding of
the first JAK inhibitor approved
by the TGA for rare blood cancer
myelofibrosis, with specific
restrictions applying.
Jakavi (ruxolitinib) is available
from today, the company said.The above article was sent to subscribers in Pharmacy Daily's issue from 01 Feb 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 01 Feb 16
MEDICATION management platform MedAdvisor Limited (MDR) showed strong financial performance for the quarter concluded on 31 Mar 2024, with operating revenue up 42% to $24.2 million from $17 million for the same period last year.
PHARMACIES in regional areas need a restructure of the 8CPA Community Service Obligation (CSO) to help fund them to support their workforce and deliver services, says the Remote and Isolated Pharmacist Association Australia (RIPAA).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.